

To

The Editorial Board of World Journal of Gastroenterology

Durham, 8/31/2018

Dear Editor,

I am sending for publication to your distinguished Journal the revision of the manuscript entitled: "The Concept of Histone Deacetylases (HDACs) in Cancer: Reflections on Esophageal Carcinogenesis and Treatment."

We would like to thank the editor and the reviewers for their kind comments on our manuscript.

All editorial editing was adopted and highlighted in the revised manuscript.

#### Reviewer Comments

1. *This is a very well written minireview, which is also timely as no other reviews are available on HDACs in esophageal cancer.*

Response: We would like to thank the reviewer for his/her comments.

2. Few recommended changes and typographical errors need to be corrected as mentioned below. In the abstract and main section, authors mention 'there are four class of HDACs.....that render them possible anti-cancer drugs, which should be rewritten as HDACs are not anti-cancer drugs instead HDAC inhibitors are being studied as anti-cancer drugs. Page 4: Change an histone to a histone Page 5: Change describe to describe Page 11: change anaugmentation to an augmentation Page 11: change Virinostat to Vorinostat Page 11: US FDA has approved 3 HDAC inhibitors, 3rd one is Belinostat approved in 2014 Page 14: delete 'it' from 'it also'

Response: All typos and grammar errors were corrected and highlighted

I declare that:

- i) the content of this paper has not been published or submitted for publication elsewhere,
- ii) all coauthors are in agreement with the content of the manuscript,
- iii) there is no financial support or relationship that may pose conflict of interest, and
- iv) no undisclosed authors contributed to the manuscript.

Respectfully,

Dimitrios Moris MD, MSc, PhD, Department of Surgery, Duke University Medical Center,  
2301 Erwin Rd, 27710, Durham, NC, USA, email: dimitrios.moris@duke.edu